Cargando…
Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway
This study aimed to use a population-based Prescription Database to explore later development of diabetes in women registered with gestational diabetes mellitus (GDM) and/or preeclampsia in the Medical Birth Registry of Norway (MBRN) during 2004–8. We used two nationwide Norwegian registries, the No...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3043244/ https://www.ncbi.nlm.nih.gov/pubmed/21298469 http://dx.doi.org/10.1007/s10654-010-9527-4 |
_version_ | 1782198612313243648 |
---|---|
author | Engeland, Anders Bjørge, Tone Daltveit, Anne Kjersti Skurtveit, Svetlana Vangen, Siri Vollset, Stein Emil Furu, Kari |
author_facet | Engeland, Anders Bjørge, Tone Daltveit, Anne Kjersti Skurtveit, Svetlana Vangen, Siri Vollset, Stein Emil Furu, Kari |
author_sort | Engeland, Anders |
collection | PubMed |
description | This study aimed to use a population-based Prescription Database to explore later development of diabetes in women registered with gestational diabetes mellitus (GDM) and/or preeclampsia in the Medical Birth Registry of Norway (MBRN) during 2004–8. We used two nationwide Norwegian registries, the Norwegian Prescription Database and the MBRN, to explore the onset of later diabetes after pregnancy complications, indicated by receiving prescriptions of drugs used to treat diabetes, in 230,000 women giving birth in 2004–8. The mean follow-up of the study cohort was 3.7 years. Five years after pregnancy, about 19 and 2% of women with GDM and preeclampsia, respectively, received drugs used to treat diabetes, compared to 0.5% of those without these complications. The risk of being dispensed drugs used to treat diabetes within the first years after pregnancy was estimated to be 41 times (95% CI: 35–47) and 3.0 times (95% CI: 2.4–3.6) higher in women with GDM and preeclampsia, respectively, compared to women without these pregnancy complications. Women with pregnancies complicated with preeclampsia or GDM had an increased risk of later diabetes, especially those having GDM. If the increase in frequency of GDM observed in MBRN in recent years is real, a further increase in diabetic women can be expected. |
format | Text |
id | pubmed-3043244 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-30432442011-04-04 Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway Engeland, Anders Bjørge, Tone Daltveit, Anne Kjersti Skurtveit, Svetlana Vangen, Siri Vollset, Stein Emil Furu, Kari Eur J Epidemiol Developmental Epidemiology This study aimed to use a population-based Prescription Database to explore later development of diabetes in women registered with gestational diabetes mellitus (GDM) and/or preeclampsia in the Medical Birth Registry of Norway (MBRN) during 2004–8. We used two nationwide Norwegian registries, the Norwegian Prescription Database and the MBRN, to explore the onset of later diabetes after pregnancy complications, indicated by receiving prescriptions of drugs used to treat diabetes, in 230,000 women giving birth in 2004–8. The mean follow-up of the study cohort was 3.7 years. Five years after pregnancy, about 19 and 2% of women with GDM and preeclampsia, respectively, received drugs used to treat diabetes, compared to 0.5% of those without these complications. The risk of being dispensed drugs used to treat diabetes within the first years after pregnancy was estimated to be 41 times (95% CI: 35–47) and 3.0 times (95% CI: 2.4–3.6) higher in women with GDM and preeclampsia, respectively, compared to women without these pregnancy complications. Women with pregnancies complicated with preeclampsia or GDM had an increased risk of later diabetes, especially those having GDM. If the increase in frequency of GDM observed in MBRN in recent years is real, a further increase in diabetic women can be expected. Springer Netherlands 2011-02-06 2011 /pmc/articles/PMC3043244/ /pubmed/21298469 http://dx.doi.org/10.1007/s10654-010-9527-4 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Developmental Epidemiology Engeland, Anders Bjørge, Tone Daltveit, Anne Kjersti Skurtveit, Svetlana Vangen, Siri Vollset, Stein Emil Furu, Kari Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway |
title | Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway |
title_full | Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway |
title_fullStr | Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway |
title_full_unstemmed | Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway |
title_short | Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway |
title_sort | risk of diabetes after gestational diabetes and preeclampsia. a registry-based study of 230,000 women in norway |
topic | Developmental Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3043244/ https://www.ncbi.nlm.nih.gov/pubmed/21298469 http://dx.doi.org/10.1007/s10654-010-9527-4 |
work_keys_str_mv | AT engelandanders riskofdiabetesaftergestationaldiabetesandpreeclampsiaaregistrybasedstudyof230000womeninnorway AT bjørgetone riskofdiabetesaftergestationaldiabetesandpreeclampsiaaregistrybasedstudyof230000womeninnorway AT daltveitannekjersti riskofdiabetesaftergestationaldiabetesandpreeclampsiaaregistrybasedstudyof230000womeninnorway AT skurtveitsvetlana riskofdiabetesaftergestationaldiabetesandpreeclampsiaaregistrybasedstudyof230000womeninnorway AT vangensiri riskofdiabetesaftergestationaldiabetesandpreeclampsiaaregistrybasedstudyof230000womeninnorway AT vollsetsteinemil riskofdiabetesaftergestationaldiabetesandpreeclampsiaaregistrybasedstudyof230000womeninnorway AT furukari riskofdiabetesaftergestationaldiabetesandpreeclampsiaaregistrybasedstudyof230000womeninnorway |